Review: Angiogenesis inhibitors in the treatment of non-small cell lung cancer

Therapeutic Advances in Medical Oncology

Volumn 1, Issue 2, 2009, Pages 95-107

  Lind, Joline S W ^a   Smit, Egbert F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

angiogenesis inhibitors; bevacizumab; non small cell lung cancer; vascular endothelial growth factor

Indexed keywords

3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; AFLIBERCEPT; ANGIOGENESIS INHIBITOR; AXITINIB; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; IRINOTECAN; MOTESANIB; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PAZOPANIB; PEMETREXED; SORAFENIB; SUNITINIB; THALIDOMIDE; VANDETANIB; VASCULOTROPIN; VATALANIB; XL 647;

CANCER COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; FATIGUE; GENE OVEREXPRESSION; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NAUSEA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TOXICITY;

EID: 77953452375     PISSN: 17588340     EISSN: None     Source Type: Journal    
DOI: 10.1177/1758834009338633     Document Type: Review

References (85)

1. Adjei, A.A., Mandrekar, S.J., Dy, G.K., Molina, J.R., Adjei, A.A., Gandara, D.R. et al. (2008) A phase II second-line study of pemetrexed (pem) in combination with bevacizumab (bev) in patients with advanced non-small cell lung cancer (NSCLC): An NCCTG and SWOG study. J Clin Oncol (Meeting Abstracts) 26: 8080.
2. Adjei, A.A., Molina, J.R., Mandrekar, S.J., Marks, R., Reid, J.R., Croghan, G. et al. (2007) Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. Clin Cancer Res 13: 2684-2691.
3. Altorki, N., Guarino, M., Lee, P., Pass, H.I., Filip, E., Bauer, T. et al. (2008) Preoperative treatment with pazopanib (GW786034), a multikinase angiogenesis inhibitor in early-stage non-small cell lung cancer (NSCLC): A proof-of-concept phase II study. J Clin Oncol (Meeting Abstracts) 26: 7557.
4. Beaudry, P., Force, J., Naumov, G.N., Wang, A., Baker, C.H., Ryan, A. et al. (2005) Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD 6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res 11: 3514-3522.
5. Blumenschein Jr, G., Sandler, A., O’Rourke, T., Eschenberg, M., Sun, Y., Gladish, G. et al. (2006) Safety and pharmacokinetics (PK) of AMG 706, panitumumab, and carboplatin/paclitaxel (CP) for the treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 24: 7119.
6. Brahmer, J.R., Govindan, R., Novello, S., Rosell, R., Belani, C.P., Atkins, J.N. et al. (2007) Efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC): Results from a phase II study. J Clin Oncol (Meeting Abstracts) 25: 7542.
7. Camp, E.R., Summy, J., Bauer, T.W., Liu, W., Gallick, G.E. and Ellis, L.M. ( 2005) Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res 11: 397-405.
8. Carmeliet, P. ( 2000) Mechanisms of angiogenesis and arteriogenesis. Nat Med 6: 389-395.
9. Cloughesy, T.F., Prados, M.D., Wen, P.Y., Mikkelsen, T., Abrey, L.E., Schiff, D. et al. (2008) A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). J Clin Oncol (Meeting Abstracts) 26: 2010b.
10. Cohen, M.H., Gootenberg, J., Keegan, P. and Pazdur, R. ( 2007) FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12: 713-718.
11. Crabb, S.J., Patsios, D., Sauerbrei, E., Ellis, P.M., Arnold, A., Goss, G. et al. (2008) Tumor Cavitation: Impact on Objective Response Evaluation in Trials of Angiogenesis Inhibitors in Non-small-cell lung Cancer. J Clin Oncol 27: 404-410.
12. D’Amato, R.J., Loughnan, M.S., Flynn, E. and Folkman, J. ( 1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91: 4082-4085.
13. Dansin, E., Mezger, J., Isla, D., Barlesi, F., Bearz, A., Lopez, P.G. et al. (2008) Safety of bevacizumab-based therapy as first-line treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): MO 19390 (SAiL). J Clin Oncol (Meeting Abstracts) 26: 8085.
14. deBoer, R., Humblet, Y., Wolf, J., Nogova, L., Ruffert, K., Milenkova, T. et al. (2008) An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer. Ann Oncol 20: 486-491.
15. DePrimo, S.E. and Bello, C. ( 2007) Surrogate biomarkers in evaluating response to anti-angiogenic agents: focus on sunitinib. Ann Oncol 18 Suppl 10: X9-X11.
16. Dowlati, A., Gray, R., Sandler, A.B., Schiller, J.H. and Johnson, D.H. ( 2008) Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab-an Eastern Cooperative Oncology Group Study. Clin Cancer Res 14: 1407-1412.
17. Duran, I., Hotte, S.J., Hirte, H., Chen, E.X., MacLean, M., Turner, S. et al. (2007) Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors. Clin Cancer Res 13: 4849-4857.
18. Ferrara, N. ( 2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25: 581-611.
19. Fontanini, G., Vignati, S., Boldrini, L., Chine, S., Silvestri, V., Lucchi, M. et al. (1997) Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 3: 861-865.
20. Fossella, F., Pereira, J.R., von Pawel, J., Pluzanska, A., Gorbounova, V., Kaukel, E. et al. (2003) Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 21: 3016-3024.
21. Gatzemeier, U., Blumenschein, G., Fosella, F., Simantov, R., Elting, J., Bigwood, D. et al. (2006) Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. J Clin Oncol (Meeting Abstracts) 24: 7002.
22. Gondek, K., Dhanda, R., Simantov, R., Gatzemeier, U., Blumenschein, G.R. and Reck, M. ( 2006) Health-related quality of life measures in advanced non-small cell lung cancer patients receiving sorafenib. J Clin Oncol (Meeting Abstracts) 24: 17085.
23. Goodman, V.L., Rock, E.P., Dagher, R., Ramchandani, R.P., Abraham, S., Gobburu, J.V. et al. (2007) Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 13: 1367-1373.
24. Goss, G.D., Laurie, S., Shepherd, F., Leighl, N., Chen, E., Gauthier, I. et al. (2007) IND.175: Phase I study of daily oral AZD 2171, a vascular endothelial growth factor receptor inhibitor (VEGFRI), in combination with gemcitabine and cisplatin (G/C) in patients with advanced non-small cell lung cancer (ANSCLC): A study of the NCIC Clinical Trials Group. J Clin Oncol (Meeting Abstracts) 25: 7649.
25. Griesinger, F., Laskin, J.J. and Pavlakis, N. ( 2008) Safety of first-line bevacizumab-based therapy with concomitant cardiovascular or anticoagulation medication in advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) in MO 19390 (SAiL). J Clin Oncol (Meeting Abstracts) 26: 8049.
26. Groen, H.J., Smit, E.F. and Dingemans, A. ( 2007) A phase II study of erlotinib (E) and bevacizumab (B) in patients (pts) with previously untreated stage IIIB/IV non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 25: 7625.
27. Hainsworth, J., Lin, M., O’Connor, P. and Herbst, R. ( 2008) A Phase III, Multicenter, Placebo-Controlled, Double-Blind, Randomized, Clinical Trial to Evaluate the Efficacy of Bevacizumab (Avastin) in Combination with Erlotinib (Tarceva) Compared with Erlotinib Alone for Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) after Failure of Standard First Line Chemotherapy (BETA), IASLC meeting 11-13 November 2008, Chicago.
28. Han, H., Silverman, J.F., Santucci, T.S., Macherey, R.S., d’Amato, T.A., Tung, M.Y. et al. (2001) Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol 8: 72-79.
29. Hanahan, D. and Weinberg, R.A. ( 2000) The hallmarks of cancer. Cell 100: 57-70.
30. Heist, R.S., Fidias, P., Huberman, M., Ardman, B., Sequist, L.V., Temel, J.S. et al. (2008) A phase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung cancer. J Thorac Oncol 3: 1153-1158.
31. Herbst, R.S., O’Neill, V.J., Fehrenbacher, L., Belani, C.P., Bonomi, P.D., Hart, L. et al. (2007) Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Chemotherapy or Erlotinib Compared With Chemotherapy Alone for Treatment of Recurrent or Refractory Non-small-cell lung Cancer. J Clin Oncol 25: 4743-4750.
32. Heymach, J.V., Hanrahan, E.O., Mann, H., Langmuir, P., Natale, R.B., Johnson, B.E. et al. (2008 a) Baseline VEGF as a potential predictive biomarker of vandetanib clinical benefit in patients with advanced NSCLC. J Clin Oncol (Meeting Abstracts) 26: 8009.
33. Heymach, J.V., Johnson, B.E., Prager, D., Csada, E., Roubec, J., Pesek, M. et al. (2007) Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 20: 4270-4277.
34. Heymach, J.V., Paz-Ares, L., de Braud, F., Sebastian, M., Stewart, D.J., Eberhardt, W.E. et al. (2008 b) Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 26: 5407-5415.
35. Ishii, H., Yazawa, T., Sato, H., Suzuki, T., Ikeda, M., Hayashi, Y. et al. (2004) Enhancement of pleural dissemination and lymph node metastasis of intrathoracic lung cancer cells by vascular endothelial growth factors (VEGFs). Lung Cancer 45: 325-337.
36. Jain, R.K. ( 2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7: 987-989.
37. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T. and Thun, M.J. ( 2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71-96.
38. Johnson, D.H., Fehrenbacher, L., Novotny, W.F., Herbst, R.S., Nemunaitis, J.J., Jablons, D.M. et al. (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22: 2184-2191.
39. Jubb, A.M., Hurwitz, H.I., Bai, W., Holmgren, E.B., Tobin, P., Guerrero, A.S., Kabbinavar, F. et al. (2006) Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and micro-vessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 24: 217-227.
40. Kane, R.C., Farrell, A.T., Saber, H., Tang, S., Williams, G., Jee, J.M. et al. (2006) Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 12: 7271-7278.
41. Kaya, A., Ciledag, A., Gulbay, B.E., Poyraz, B.M., Celik, G., Sen, E. et al. (2004) The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients. Respir Med 98: 632-636.
42. Kelly, K., Crowley, J., Bunn Jr, P.A., Presant, C.A., Grevstad, P.K., Moinpour, C.M. et al. (2001) Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 19: 3210-3218.
43. Kindler, H.L., Friberg, G., Singh, D.A., Locker, G., Nattam, S., Kozloff, M. et al. (2005) Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23: 8033-8040.
44. Kiura, K., Nakagawa, K., Shinkai, T., Eguchi, K., Ohe, Y., Yamamoto, N. et al. (2008) A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J Thorac Oncol 3: 386-393.
45. Kreisl, T.N., Kim, L., Moore, K., Duic, P., Royce, C., Stroud, I. et al. (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27: 740-745.
46. Laurie, S.A., Gauthier, I., Arnold, A., Shepherd, F.A., Ellis, P.M., Chen, E. et al. (2008) Phase I and pharmacokinetic study of daily oral AZD 2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group. J Clin Oncol 26: 1871-1878.
47. Le Chevalier, T., Scagliotti, G., Natale, R., Danson, S., Rosell, R., Stahel, R. et al. (2005) Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 47: 69-80.
48. Lee, S.-M., Woll, P.J., Rudd, R.M., Gower, N.H., Ottensmeier, C.H., Ali, K. et al. (2007) A phase III randomised, double blind, placebo controlled trial of gemcitabine/carboplatin with or without thalidomide in advanced non-small cell lung cancer (NSCLC): C 1-03. Journal of Thoracic Oncology 2: S359.
49. LeTourneau, C., Vidal, L. and Siu, L.L. ( 2008) Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents. Drug Resist Updat 11: 99-109.
50. Liu, B., Barrett, T., Choyke, P., Maynard, K., Wright, J., Kummar, S. et al. (2006) A phase II study of BAY 43-9006 (Sorafenib) in patients with relapsed non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 24: 17119.
51. Llovet, J.M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.F. et al. (2008) Sorafenib in Advanced Hepatocellular Carcinoma. N Engl J Med 359: 378-390.
52. Manegold, C., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsch, V. et al. (2008) BO17704 (AVAIL): A phase III randomised study of first-line bevacizumab combined with cisplatin/gemcitabine (CG) in patients (pts) with advanced or recurrent non-squamous, non-small cell lung cancer (NSCLC). Ann Oncol 19: viii1-viii4.
53. Massarelli, E., Miller, V.A., Leighl, N.B., Rosen, P.J., Albain, K.S., Hart, L.L. et al. (2007) Phase II study of the efficacy and safety of intravenous (IV) AVE 0005 (VEGF Trap) given every 2 weeks in patients (Pts) with platinum- and erlotinib- resistant adenocarcinoma of the lung (NSCLA). J Clin Oncol (Meeting Abstracts) 25: 7627.
54. Miller, A.A., Case, D., Atkins, J.N., Giguere, J.K. and Bearden, J.D. ( 2006) Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer. J Thorac Oncol 1: 832-836.
55. Natale, R.B., Bodkin, D., Govindan, R., Sleckman, B., Rizvi, N., Capo, A. et al. (2006) ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized phase II trial. J Clin Oncol (Meeting Abstracts) 24: 7000.
56. Nieder, C., Andratschke, N., Jeremic, B. and Molls, M. ( 2003) Comparison of serum growth factors and tumor markers as prognostic factors for survival in non-small cell lung cancer. Anticancer Res 23: 5117-5123.
57. Nikolinakos, P., Altorki, N., Guarino, M., Tran, H., Rajagopalan, D., Swann, S. et al. (2008) Analyses of plasma cytokine/angiogenic factors (C/AFs) profile during preoperative treatment with pazopanib (GW786034) in early-stage non-small cell lung cancer. J Clin Oncol (Meeting Abstracts) 26: 7568.
58. Norden, A.D., Young, G.S., Setayesh, K., Muzikansky, A., Klufas, R., Ross, G.L. et al. (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70: 779-787.
59. Norden-Zfoni, A., Desai, J., Manola, J., Beaudry, P., Force, J., Maki, R. et al. (2007) Blood-based biomarkers of SU 11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 13: 2643-2650.
60. O’Byrne, K.J., Koukourakis, M.I., Giatromanolaki, A., Cox, G., Turley, H., Steward, W.P. et al. (2000) Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer 82: 1427-1432.
61. O’Reilly, M.S. ( 2008) The interaction of radiation therapy and antiangiogenic therapy. Cancer J 14: 207-213.
62. Paravar, T. and Lee, D.J. ( 2008) Thalidomide: mechanisms of action. Int Rev Immunol 27: 111-135.
63. Patel, J.D., Hensing, T.A., Rademaker, F., Hart, E., Obasaju, C.K., Treat, J. et al. (2008) Pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for advanced non-squamous non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 26: 8044.
64. Reck, M., von, P.J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V. et al. (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27: 1227-1234.
65. Sandler, A., Gray, R., Perry, M.C., Brahmer, J., Schiller, J.H., Dowlati, A. et al. (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542-2550.
66. Sandler, A., Yi, J., Hambleton, J., Kolb, M.M., and Johnson, D.H. ( 2008) Treatment Outcomes By Tumor Histology In Eastern Cooperative Group (ECOG) Study E 4599 Of Bevacizumab (BV) With Paclitaxel/carboplatin (PC) For Advanced Non-small Cell Lung Cancer (NSCLC), poster 133, IASLC meeting 13-15 November 2008, Chicago.
67. Sandler, A.B., Schiller, J.H., Gray, R., Dimery, I., Brahmer, J., Samant, M. et al. (2009) Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab. J Clin Oncol 27: 1405-1412.
68. Scagliotti, G.V., de Marinis, F., Rinaldi, M., Crino, L., Gridelli, C., Ricci, S. et al. (2002) Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 20: 4285-4291.
69. Scagliotti, G.V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C. et al. (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26: 3543-3551.
70. Schiller, J.H., Harrington, D., Belani, C.P., Langer, C., Sandler, A., Krook, J. et al. (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98.
71. Schiller, J.H., Lee, J.W., Hanna, N.H., Traynor, A.M. and Carbone, D.P. ( 2008) A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E 2501. J Clin Oncol (Meeting Abstracts) 26: 8014.
72. Shaked, Y., Henke, E., Roodhart, J.M., Mancuso, P., Langenberg, M.H., Colleoni, M. et al. (2008) Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 14: 263-273.
73. Shepherd, F.A., Rodrigues, P.J., Ciuleanu, T., Tan, E.H., Hirsh, V., Thongprasert, S. et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132.
74. Socinski, M.A., Novello, S., Brahmer, J.R., Rosell, R., Sanchez, J.M., Belani, C.P. et al. (2008) Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 26: 650-656.
75. Somer, R.A., Sherman, E. and Langer, C.J. ( 2008) Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: the implications of Eastern Cooperative Oncology Group 4599. Clin Lung Cancer 9: 102-105.
76. Strijbos, M.H., Gratama, J.W., Kraan, J., Lamers, C.H., den Bakker, M.A. and Sleijfer, S. ( 2008) Circulating endothelial cells in oncology: pitfalls and promises. Br J Cancer 98: 1731-1735.
77. Therasse, P., Arbuck, S.G., Eisenhauer, E.A., Wanders, J., Kaplan, R.S., Rubinstein, L. et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
78. Vredenburgh, J.J., Desjardins, A., Herndon, J.E., Marcello, J., Reardon, D.A., Quinn, J.A. et al. (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25: 4722-4729.
79. Vroling, L., van der Veldt, A., de Haas, R., Schuurhuis, G.J., van Cruijsen, H., van den Eertwegh, A. et al. (2008) CD34bright/CD133neg candidate circulating endothelial progenitor cells (ccEPCs) are a potential biomarker during treatment with sunitinib or bevacizumab. AACR Meeting Abstracts 2008: 4956.
80. Waples, J.M., Auerbach, M., Steis, R., Boccia, R.V. and Wiggans, R.G. ( 2008) A phase II study of oxaliplatin and pemetrexed plus bevacizumab in advanced non-squamous non-small cell lung cancer (An International Oncology Network study, #I-04-015). J Clin Oncol (Meeting Abstracts) 26: 19018.
81. Wilhelm, S.M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H. et al. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099-7109.
82. Willett, C.G., Boucher, Y., Duda, D.G., di Tomaso, E., Munn, L.L., Tong, R.T. et al. (2005) Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 23: 8136-8139.
83. Woodburn, J.R. ( 1999) The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82: 241-250.
84. Yuan, A., Yu, C.J., Kuo, S.H., Chen, W.J., Lin, F.Y., Luh, K.T. et al. (2001) Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J Clin Oncol 19: 432-441.
85. Zebrowski, B.K., Yano, S., Liu, W., Shaheen, R.M., Hicklin, D.J., Putnam Jr, J.B. et al. (1999) Vascular Vi endothelial growth factor levels and induction h of permeability in malignant pleural effusions. Clin Cancer Res 5: 3364-3368.